OBJECTIVE: To investigate the mitogenic and anti-apoptotic effects of transforming growth factor beta 1 (TGF beta 1) on rheumatoid synovial cells in vitro. METHODS: Synovial cells were cultured with or without TGF beta 1. After incubation, the proliferative response of synovial cells and the expression of Fas antigen and bcl-2 on synovial cells were examined. Finally, Fas antigen-mediated apoptosis of synovial cells was investigated by the addition of anti-Fas antibody. RESULTS: TGF beta 1 enhanced the proliferation of synovial cells in a dose-dependent manner. In addition, Fas antigen expression on synovial cells was inhibited by the addition of TGF beta 1 with up-regulation of bcl-2 expression. The addition of anti-Fas antibody induced synovial cell apoptosis. However, stimulation of synovial cells with TGF beta 1 became markedly resistant to Fas antigen-mediated apoptosis. The results were not affected by the addition of a neutralizing antibody to platelet-derived growth factor type AA (PDGF-AA), which suggests that the effect of TGF beta 1 on synovial cells was promoted via PDGF-AA-independent mechanisms. CONCLUSION: Our results suggest that TGF beta 1 promotes synovial cell proliferation through its mitogenic effect on synovial cells and interference with the apoptotic process mediated by the Fas antigen, resulting in the perpetuation of the synovial hyperplasia in patients with rheumatoid arthritis.
OBJECTIVE: To investigate the mitogenic and anti-apoptotic effects of transforming growth factor beta 1 (TGF beta 1) on rheumatoid synovial cells in vitro. METHODS: Synovial cells were cultured with or without TGF beta 1. After incubation, the proliferative response of synovial cells and the expression of Fas antigen and bcl-2 on synovial cells were examined. Finally, Fas antigen-mediated apoptosis of synovial cells was investigated by the addition of anti-Fas antibody. RESULTS:TGF beta 1 enhanced the proliferation of synovial cells in a dose-dependent manner. In addition, Fas antigen expression on synovial cells was inhibited by the addition of TGF beta 1 with up-regulation of bcl-2 expression. The addition of anti-Fas antibody induced synovial cell apoptosis. However, stimulation of synovial cells with TGF beta 1 became markedly resistant to Fas antigen-mediated apoptosis. The results were not affected by the addition of a neutralizing antibody to platelet-derived growth factor type AA (PDGF-AA), which suggests that the effect of TGF beta 1 on synovial cells was promoted via PDGF-AA-independent mechanisms. CONCLUSION: Our results suggest that TGF beta 1 promotes synovial cell proliferation through its mitogenic effect on synovial cells and interference with the apoptotic process mediated by the Fas antigen, resulting in the perpetuation of the synovial hyperplasia in patients with rheumatoid arthritis.
Authors: M Kawakami; K Suzuki; Y Matsuki; T Ishizuka; T Hidaka; T Konishi; M Matsumoto; K Kataharada; H Nakamura Journal: Ann Rheum Dis Date: 1998-10 Impact factor: 19.103
Authors: S Yamasaki; A Kawakami; T Nakashima; H Nakamura; M Kamachi; S Honda; Y Hirai; A Hida; H Ida; K Migita; Y Kawabe; T Koji; I Furuichi; T Aoyagi; K Eguchi Journal: Ann Rheum Dis Date: 2001-07 Impact factor: 19.103
Authors: A Hida; A Kawakami; T Nakashima; S Yamasaki; H Sakai; S Urayama; H Ida; H Nakamura; K Migita; Y Kawabe; K Eguchi Journal: Immunology Date: 2000-04 Impact factor: 7.397
Authors: T Miyashita; A Kawakami; T Nakashima; S Yamasaki; M Tamai; F Tanaka; M Kamachi; H Ida; K Migita; T Origuchi; K Nakao; K Eguchi Journal: Clin Exp Immunol Date: 2004-08 Impact factor: 4.330
Authors: A Kawakami; N Matsuoka; M Tsuboi; S Urayama; T Nakashima; Y Kawabe; T Koji; T Aoyagi; K Maeda; K Eguchi Journal: Immunology Date: 1998-09 Impact factor: 7.397
Authors: H Nakamura; T Koji; M Tominaga; A Kawakami; K Migita; Y Kawabe; T Nakamura; S Shirabe; K Eguchi Journal: Clin Exp Immunol Date: 1998-10 Impact factor: 4.330
Authors: S Wakisaka; N Suzuki; Y Takeba; Y Shimoyama; H Nagafuchi; M Takeno; N Saito; T Yokoe; A Kaneko; T Asai; T Sakane Journal: Clin Exp Immunol Date: 1998-10 Impact factor: 4.330